News | January 31, 2022
Cipla has strong traction in India and the US: ICICI Direct
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
This funding will help the start-up consolidate its position as a one-stop destination for pet parents as they holistically reimagine the entire pet care ecosystem
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
